Your browser doesn't support javascript.
loading
Clinical significance of isolated tumor cells and micrometastasis in low-grade, stage I endometrial cancer.
Piedimonte, Sabrina; Richer, Lara; Souhami, Luis; Arseneau, Jocelyne; Fu, Lili; Gilbert, Lucy; Alfieri, Joanne; Jardon, Kris; Zeng, Xing Ziggy.
Afiliação
  • Piedimonte S; Department of Obstetrics and Gynecology, McGill University Health Center, Montreal, Canada.
  • Richer L; Department of Pathology, McGill University Health Center, Montreal, Canada.
  • Souhami L; Department of Radiation Oncology, McGill University Health Center, Montreal, Canada.
  • Arseneau J; Department of Pathology, McGill University Health Center, Montreal, Canada.
  • Fu L; Department of Pathology, McGill University Health Center, Montreal, Canada.
  • Gilbert L; Department of Obstetrics and Gynecology, McGill University Health Center, Montreal, Canada.
  • Alfieri J; Department of Gynecologic Oncology, McGill University Health Center, Montreal, Canada.
  • Jardon K; Department of Radiation Oncology, McGill University Health Center, Montreal, Canada.
  • Zeng XZ; Department of Gynecologic Oncology, McGill University Health Center, Montreal, Canada.
J Surg Oncol ; 118(7): 1194-1198, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30353577
INTRODUCTION: Ultrastaging in endometrial cancer (EC) led to increased detection of isolated tumor cells (ITC, ≤0.2 mm) and micrometastases (MM, 0.2-2 mm), with unclear effect on prognosis. Our aim was to characterize the impact of ITC and MM on the outcome of these patients. METHODS: Grade 1 to 2 stage I endometrioid EC patients with nodal ITC (n = 11) or MM (n = 12) between 2012 and 2018 were retrospectively compared to a matched group of lymph node negative (n = 18) patients based on age, body mass index, grade, myometrial invasion, and lymphovascular space invasion (LVI) status using propensity score analysis (1:1). Mann-Whitney U tests were performed on continuous variables and χ2 tests on categorical variables. Progression-free survival (PFS) was the main endpoint. RESULTS: All MM and 81% of ITC had LVI. More ITC/MM patients received RT and chemotherapy (91.7% vs 18.4%; 70.8% vs 4.5%, respectively; P < 0.01) without significant difference in treatment-related toxicities (25% vs 27.3% grade 1%-2% and 20.8% vs 9.1% grade 2-3; P = 0.538) or PFS (29.2 vs 25 months; P = 0.828). Two distant recurrences occurred in MM patients after 2.5 years; one lung and one para-aortic lymph node. CONCLUSION: With adjuvant treatment, ITC/MM in otherwise well-differentiated stage I endometrial cancer have similar outcomes to matched LN- patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Intervalo Livre de Doença / Micrometástase de Neoplasia / Linfonodos / Metástase Linfática Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: J Surg Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Intervalo Livre de Doença / Micrometástase de Neoplasia / Linfonodos / Metástase Linfática Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: J Surg Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá